JPMorgan Chase & Co. (NYSE: JPM) finished Friday's session at $362.84, a marginal 0.07% decline, as investors largely shrugged off news that the bank had severed its banking relationship with prediction market platform Polymarket due to regulatory concerns. The stock now sits just 1.0% below its 52-week high of $366.50, reflecting a resilient market sentiment despite the compliance-driven decision.
The modest market reaction underscores that the move is viewed as a proactive regulatory step rather than a financial setback. Trading volume on Friday reached 5.06 million shares, which is 57% of JPMorgan's 65-day average, indicating that the news did not trigger significant investor activity.
According to a source familiar with the matter, JPMorgan terminated its relationship with Polymarket in October 2025, citing regulatory issues. Polymarket has stated that it continues to maintain connections with JPMorgan through separate entities and business activities. The report did not disclose the revenue impact or mention any new fines, charges, or capital requirements for the bank.
This development comes amid heightened regulatory scrutiny of prediction markets. In January 2022, the Commodity Futures Trading Commission fined Polymarket $1.4 million for offering off-exchange event contracts and ordered noncompliant markets to close. More recently, New York City Council Speaker Julie Menin alleged that prediction-market firms use predatory marketing tactics, and in July, the New York attorney general filed a lawsuit against competitor Kalshi for violating state gambling regulations.
Despite these concerns, JPMorgan's fundamentals remain robust. The bank reported second-quarter net income of $21.2 billion, up 41% year-over-year, with total managed revenue of $58.0 billion, a 27% increase. Markets revenue surged 35% to $12.1 billion, equities revenue jumped 86% to $6.0 billion, and investment-banking fees rose 30% to $3.3 billion.
CEO Jamie Dimon described the market environment as "healthy, active" but cautioned about its longevity. This cautious outlook may have more bearing on near-term earnings than the termination of a single fintech partnership.
Analyst price targets for JPMorgan vary widely, reflecting divergent views on valuation. BofA Securities and Barclays have a Buy and Overweight rating respectively, with targets of $420, implying a 15.8% upside. Wells Fargo and RBC Capital are more conservative, with targets of $375 and $370, while Citigroup and Baird have Neutral ratings with targets of $360 and $305, respectively.
As U.S. markets reopen on Monday, traders will be watching whether the initial calm persists with higher liquidity. Any further regulatory actions or disclosures could shift the outlook. While the Polymarket case raises compliance questions, it has not yet impacted JPMorgan's profit trajectory, and the stock's proximity to its peak suggests investor confidence remains strong.
